Quantum Immunologics, Inc. Announces Collaboration With Auburn University Veterinary College to Commercialize Veterinary Cancer Immunotherapy

TAMPA, FL--(Marketwire - November 25, 2009) - Quantum Immunologics, Inc. (QI), a privately held biotechnology company, announced today that it has entered into a Collaboration Agreement with Auburn University to bring its novel cancer immunotherapy to the veterinary market. The parties have agreed to form a new, independently-funded and jointly owned company to accomplish its goal. Along with providing corporate and administrative management of the new company, QI will license its proprietary oncofetal antigen-based therapy to serve as the collaboration's underlying technology. The partnership will draw upon Auburn University's College of Veterinary Medicine companion animal oncology expertise, along with its substantial animal clinical trial experience. According to QI's CEO, Chuck Broes, "This collaboration provides a 'best of both worlds' approach. We have a tremendous respect for Auburn's renowned veterinary institution and believe that this collaboration provides a natural synergy, allowing both parties to maximize one another's core competencies. We also believe that this initiative will allow QI to capitalize upon the significant veterinary market, thereby enhancing shareholder value." QI anticipates that the new company will begin operations in mid-2010.

About Quantum Immunologics

Quantum Immunologics is dedicated to the research, development and production of products and services that will promote unique, individualized immunologic cancer treatment and early detection technologies with a high rate of efficacy, minimal side effects and greatly reduced cost compared to current treatments.

Quantum Immunologics has received FDA authorization to apply its exclusively licensed patented immunotherapy in a Phase I/II human clinical study. QI's Phase I/II clinical trial, which involves a cohort of 27 patients with advanced-stage metastatic breast cancer, is designed around the use of QI's proprietary dendritic cell therapy, which employs oncofetal antigen ("OFA") to recruit the patient's own immune system to target and combat the cancer cells with the intent to improve patient survivability and quality of life.

For more information about QI and its FDA-authorized trials, please visit www.quantumimmunologics.com, or contact Investor Relations at (813) 849-7859.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include, but are not limited to, statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Quantum Immunologics, Inc. undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.